#LiverHealth Archives - Page 2 of 4

AASLD 2024丨Artificial Intelligence Enhancing Early Diagnosis of Metabolic Associated Steatotic Liver Disease

By Mourabit Halima 2024.11.21

At the 2024 Annual Meeting of the American Association for the Study of Liver Diseases (AASLD) held on November 15 in San Diego, California, a groundbreaking study highlighted the transformative…

Dr. Lai Wei: Interpretation of Key Points from the 2024 Edition of the Chinese Guidelines for the Prevention and Treatment of Metabolic (Non-Alcoholic

By Lisa Cui 2024.10.15

Editor's note: Liver diseases, primarily viral hepatitis, metabolic-associated fatty liver disease (MAFLD), and alcoholic liver disease, affect approximately 400 million people in China. With the increasing pace of life, unhealthy…

JOH丨Optimizing Algorithms to Narrow the Gray Zone in Diagnosing Clinically Significant Portal Hypertension

By Peter W. PENG 2024.10.12

Editor’s note: Portal hypertension (PHT) in cirrhosis is a leading cause of complications in patients with compensated chronic liver disease (cACLD). Clinically significant portal hypertension (CSPH) is closely linked to…

Gastroenterology丨Dr. Chuanlong Zhu: Analysis of a Rare Cause of Long-term Abnormal Liver Function in a Male Patient

By Mourabit Halima 2024.09.22

On August 27, 2024, the team led by Dr. Chuanlong Zhu from the Infectious Diseases Department at Jiangsu Province Hospital (The First Affiliated Hospital with Nanjing Medical University) published a…

JOH | Predictive Factors for Hepatitis Flares after Stopping Nucleos(t)ide Analogs

By Peng Longmei 2024.09.17

According to the World Health Organization (WHO), approximately 296 million people globally suffer from chronic hepatitis B (CHB). Despite the advent of new therapies, long-term treatment with nucleos(t)ide analogs (NAs)…

Dr. Bo Feng: Classification and Differentiation of Hepatic Vascular Lesions

By Peter W. PENG 2024.09.13

Editor's Note: Hepatic vascular diseases include lesions in the hepatic artery, portal vein, hepatic vein, and hepatic sinusoids. Due to the lack of specific clinical manifestations, and differences in the…

Delicate and Thin Fibrous Septa Indicate a Regression Tendency in MASH Patients with Advanced Fibrosis

By Mourabit Halima 2024.09.11

Editor’s Note: Metabolic dysfunction-associated steatohepatitis (MASH) represents a severe subtype of metabolic dysfunction-associated fatty liver disease (MAFLD), a global public health issue affecting over 25% of the global population. MASH…

JOH | New Machine Learning Model Accurately Predicts Risk of Liver-Related Complications After Chronic Hepatitis B Cure

By Lisa Cui 2024.09.11

Recently, a research team led by Dr. Jeong-Hoon Lee from Seoul National University College of Medicine made significant strides in predicting the risk of liver-related outcomes (LROs) after functional cure…

Alerting Liver Damage Caused by Lead Poisoning Accompanied by Abdominal Pain and Anemia: Diagnostic and Treatment Approach of a Rare Case

By Yin, Jiale 2024.09.08

Authors: Liang Zhang, Jianping Qin, Shanhong Tang Institution: Department of Gastroenterology, General Hospital of Western Theater Command Editor's Note: To help clinicians broaden their horizons and enrich their practical skills…

Hepatology丨Chinese Researchers Confirm that the EAT-Lancet Diet Significantly Reduces the Risk of Metabolic-Associated Fatty Liver Disease

By Mourabit Halima 2024.09.02

Editor's Note With the global rise in obesity, diabetes, and metabolic syndrome, the prevalence of metabolic-associated fatty liver disease (MASLD) is also increasing. Statistics show that MASLD has become one…